Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Caution over antibiotics alternative
Researchers are urging caution over new drug alternatives to antibiotics
Researchers are urging caution over new drug alternatives to antibiotics
New drugs could aid spread of disease, researchers say

Scientists says new types of drugs which limit the symptoms of an infection, rather than killing it as with antibiotics, need further study to measure their long term consequences.

The new types of drugs are being developed by the pharmaceutical industry as an alternative to antibiotics, to overcome the widespread problem of infections becoming antibiotic resistant.

Rather than killing an infection, the new drugs will limit the symptoms caused by a bug or virus in the body,  enabling the patient to tolerate disease, and buying the immune system time to defeat the infection naturally.

Researchers from the Universities of Edinburgh and Liverpool have been using a mathematical model to look at how at how these new drugs could affect how infections spread and evolve.

They found that in cases where the symptoms are not linked to the spread of disease, these drugs may prevent an infection from evolving too quickly, and the drugs will be useful.

But in other cases, the drugs will lead to people who appear healthy, but who are highly infectious and so more likely to pass on the disease.

The research study was published in PLoS Biology.

Dr Pedro Vale, of the University of Edinburgh's School of Biological Sciences, said: "In treating infections with drugs, we change their environment, but bacteria and other infectious agents are incredibly good at adapting to their environment.

"Damage limitation therapies may be a useful alternative to antibiotics, but we should be cautious, and investigate their potential long-term consequences. Limiting damage may work for the individual, but could, in some cases, increase disease spread."

 

Become a member or log in to add this story to your CPD history

Equine Disease Surveillance report released for Q4 2025

News Story 1
 The latest Equine Disease Surveillance report has been released, with details on equine disease from Q4 of 2025.

The report, produced by Equine Infectious Disease Surveillance, includes advice on rule changes for equine influenza vaccination.

Statistics and maps detail recent outbreaks of equine herpes virus, equine influenza, equine strangles and equine grass sickness. A series of laboratory reports provides data on virology, bacteriology, parasitology and toxicosis.

This issue also features a case study of orthoflavivus-associated neurological disease in a horse in the UK. 

Click here for more...
News Shorts
RCVS annual renewal fee for vets due

RCVS' annual renewal fee for veterinary surgeons is now due. Vets must pay their renewal fee before Wednesday, 1 April 2026.

This year's standard annual fee has increased to 431 from last year's 418. This is an approximately three per cent increase, as approved by RCVS Council and the Privy Council.

Tshidi Gardner, RCVS treasurer, said: "The small fee increase will be used to help deliver both our everyday activities and our new ambitious Strategic Plan, which includes aims such as achieving new legislation, reviewing the Codes of Professional Conduct and supporting guidance, and continuing to support the professions through activities such as the Mind Matters Initiative, RCVS Academy and career development."

A full breakdown of the new fees is on the RCVS website. Information about tax relief is available on the UK government website.